NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of$0.03 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.02 per share when it actually produced break-even earnings, delivering a surprise of +100%.Over the last four quarters, the company has surpassed consensus EPS estimates three ...